Browse the evidence

Adhering to an anti-inflammatory diet (low Dietary Inflammatory Index) does not improve perceived stress or general health outcomes during caloric restriction in healthy, non-obese adults.

If you are restricting calories to lose weight, do not expect that focusing specifically on 'anti-inflammatory' foods will automatically lower your stress levels or improve your general health perception. The CALERIE trial shows that while CR itself may improve general health, the specific inflammatory potential of the diet (DII) does not drive these psychological benefits. Focus on sustainable caloric deficit rather than obsessing over anti-inflammatory metrics for mental health gains.

Standard questionnaires (7dPAR, BWHS) and prediction equations (DRI, BOD POD) are valid for estimating Total Energy Expenditure (TEE) at a group level but lack sufficient accuracy for individual assessment due to wide limits of agreement and low correlation with the gold standard (DLW).

Use questionnaires and standard equations to estimate your energy needs for general planning or group studies, but do not rely on them for precise individual calorie targets. The error margin is too large (potentially ±1000+ kcal) for effective individual weight management. For individual precision, more rigorous testing or metabolic assessment is required.

Short-term overnutrition directly impairs thyroid hormone biosynthesis and peripheral T4-to-T3 conversion, causing hypothyroidism and reduced energy expenditure, despite compensatory thyroidal adaptations.

Obesity can directly damage thyroid function and slow metabolism, creating a vicious cycle. However, this damage is largely reversible with weight loss. Focus on sustainable caloric reduction rather than seeking thyroid fixes alone, as the thyroid dysfunction is a symptom of overnutrition, not the root cause.

Overnutrition reduces whole-body energy expenditure by impairing peripheral T4-to-T3 conversion via decreased D2 activity, rendering obese individuals resistant to T4 therapy.

Obesity impairs your body's ability to convert T4 into active T3, which lowers your metabolism and makes T4 supplements less effective for weight loss. The solution is not more thyroid medication, but weight loss, which restores normal thyroid function.

Off-label use of GLP-1 agonists by healthy athletes for aesthetic or performance purposes raises ethical, legal, and safety concerns, including potential classification as doping and inequality in sports access.

Using GLP-1 agonists off-label for aesthetic or performance reasons is not approved and carries ethical and legal risks. It may be viewed as doping and creates inequality in sports. Athletes should consult regulatory bodies and prioritize approved medical indications over off-label use for performance enhancement.

Genotype-based dietary interventions (low-carb vs. low-fat) do not significantly impact weight loss outcomes, suggesting that genotyping alone is not an effective precision medicine approach for weight loss.

Don't pay for expensive genetic testing to tell you whether to eat low-carb or low-fat. Current high-quality evidence shows that your genotype does not predict whether you will lose more weight on one diet versus the other. Focus on finding a dietary pattern you can adhere to consistently that creates a caloric deficit.

Tirzepatide administration (2.5-15 mg weekly) causes injection-site reactions (ISRs) in 2-8% of patients, presenting as localized erythema, swelling, or pruritus, which are generally mild, self-limiting, and comparable in frequency to other GLP-1 agonists.

Expect mild redness or itching at the injection site in the first few weeks. This is common and usually goes away on its own. Rotate your injection sites (abdomen, thigh, upper arm) and use clean needles to reduce irritation. If you get a rash that spreads or doesn't go away, contact your doctor.

Tirzepatide use is associated with rare but serious hypersensitivity reactions, including anaphylaxis and angioedema, occurring in approximately 1-4% of patients, often linked to anti-drug antibodies but not always causally related.

Watch for signs of a severe allergic reaction, such as swelling of the face/throat, difficulty breathing, or widespread hives. These are rare but serious. If you experience them, seek emergency medical help immediately. Most skin reactions are mild and go away on their own.

Excess and dysfunctional epicardial adipose tissue (EAT) contributes to coronary microvascular dysfunction (CMD) and vasospastic angina (VSA) through pro-inflammatory signaling, oxidative stress, and smooth muscle hyperreactivity.

If you have chest pain with normal arteries (CMD or VSA), reducing epicardial fat through lifestyle or medication may improve symptoms by lowering inflammation and improving blood vessel function.

GLP-1 receptor agonist utilization for obesity has increased significantly and disproportionately among women compared to men, with obesity emerging as a key predictor of use specifically in female patients.

If you are a woman with obesity, you are significantly more likely to be prescribed a GLP-1RA than a man with similar characteristics, particularly after 2021. This utilization gap is driven by stronger associations between obesity and prescription in women. Men should be aware that they may face lower prescription rates and should proactively discuss weight management options with their providers.

Depression is uniquely and significantly associated with increased GLP-1RA utilization in women, suggesting a complex interplay between mental health comorbidities and medication access.

For women, having a diagnosis of depression is linked to a higher likelihood of being prescribed GLP-1RAs. This may reflect targeted prescribing or the complex relationship between mental health and weight management. It highlights the need for sex-sensitive screening and holistic care that addresses both metabolic and psychiatric health.

Maxillomandibular advancement (MMA) surgery achieves the largest and most durable reductions in OSA severity, with efficacy comparable to CPAP.

If you have severe sleep apnea and cannot use CPAP, ask about Maxillomandibular Advancement (MMA) surgery. It is a major surgery but can provide a permanent, CPAP-level reduction in apnea events for the right candidate.

There are confirmed cases of falsified GLP-1 receptor agonists in Brazil, indicating supply chain vulnerabilities.

Counterfeit GLP-1 drugs have been confirmed in Brazil. Patients should obtain medications through regulated channels to avoid falsified products.

The presence of anti-drug antibodies (ADAs) to GLP-1 receptor agonists does not necessarily neutralize their clinical efficacy, although it may increase the risk of hypersensitivity reactions.

If you develop antibodies to your GLP-1 medication, it does not automatically mean it has stopped working for weight loss. However, you may experience more injection site reactions. Discuss these symptoms with your doctor; they may not need to stop the drug unless side effects are severe.

Intensive lifestyle interventions (diet and exercise) alone are insufficient to prevent significant weight regain after discontinuation of incretin-based therapy, although they may modestly attenuate the rebound.

Even if you commit to intense diet and exercise after stopping your weight loss medication, you will likely regain a significant amount of weight. Lifestyle changes are important for your health, but they are not a substitute for the medication's hormonal effects in preventing regain.

GLP-1 and GIP receptor agonists improve hepatic outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), including resolution of MASH and improvement in fibrosis.

GLP-1 therapies can significantly improve liver health in patients with MASH, including resolving the disease and improving fibrosis in many cases. This benefit is partly due to weight loss but also involves direct effects on liver tissue. Early treatment is crucial, as benefits are not seen in advanced cirrhosis. Patients with fatty liver should discuss these options with their doctor.

GLP-1 receptor agonists (GLP-1RAs) cause frequent, dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation, reflux) that typically diminish over time but are a major cause of treatment discontinuation.

If you start a GLP-1 medication, expect digestive issues like nausea or diarrhea in the first few months. These symptoms are very common (affecting half to 60% of users) and are usually dose-dependent. The good news is that they typically get better over time. Starting with a lower dose and increasing slowly can help manage this.

GLP-1RAs are associated with an increased risk of hypoglycemia, particularly when combined with insulin or sulfonylureas, although the risk remains lower than with those agents alone.

If you take a GLP-1 medication along with insulin or sulfonylureas, your risk of low blood sugar (hypoglycemia) increases. However, this risk is still lower than if you were taking insulin or sulfonylureas alone. Monitor your blood sugar as advised by your doctor.

Sarcopenia is driven by anabolic resistance, mitochondrial dysfunction, and chronic inflammation, which decouple muscle mass from muscle function.

Understanding that muscle mass and function are different helps explain why you might look stronger but still feel weak. Treating the underlying inflammation and mitochondrial health is as important as building size.

Targeting HDL-C and Triglycerides with non-statin drugs (niacin, fibrates) added to statins does not provide additional cardiovascular benefit compared to statin therapy alone in most cases.

If you are already taking a statin, adding niacin or fibrates to fix your HDL or triglycerides usually does not provide extra protection against heart attacks. Stick to your statin and lifestyle changes, as these are the most proven strategies.

Moderate alcohol consumption (up to 36 g/day) in type 2 diabetes patients is associated with reduced mortality and microvascular/macrovascular complications.

If you have type 2 diabetes, moderate alcohol intake (up to 36 grams per day) may actually lower your risk of heart problems and other complications. This contradicts the common advice to avoid alcohol completely. However, this does not mean you should start drinking if you don't already.

Sulfonylureas have fewer cardiovascular side effects and similar mortality to metformin, with clinically irrelevant weight gain and rare hypoglycemia.

Sulfonylureas are often viewed negatively, but they may have fewer heart-related side effects than metformin and do not significantly impact mortality. Weight gain is minimal, and low blood sugar is rare. They remain a safe and effective option for many patients.

Metabolic surgery (RYGB/VSG) improves glycemic control and induces T2DM remission through weight-loss-independent mechanisms, specifically by altering bile acid metabolism (FXR/TGR5 pathways), increasing incretin hormones (GLP-1/PYY), and modulating the gut microbiome, in addition to caloric restriction.

Metabolic surgery works by changing how your body processes food signals (hormones and bile acids), not just by making you eat less. This reset can lead to diabetes remission even before significant weight loss occurs, suggesting that the procedure alters the underlying biology of insulin resistance.

Metabolic surgery increases circulating levels of bile acids (BAs), which activate FXR and TGR5 receptors to suppress gluconeogenesis, improve insulin resistance, and stimulate GLP-1 secretion, thereby improving glucose homeostasis.

Surgery changes bile acid flow and concentration, which acts as a signaling molecule to tell the liver to stop producing excess sugar and to stimulate hormones that help insulin work better.